Stock of Moderna Inc.
mRNA,
rose 1.2% after the drugmaker said it sold $6.7 billion in products in 2023. Analysts expected the company to sell $6.35 billion in products in 2023. Moderna said its share of the U.S. COVID-19 drug market was 48% in 2023, up from 37% in 2022. It also continues to expect product sales of about $4 billion. dollars in 2024, compared to $4.4 billion estimated by analysts. Moderna continues to expect a return to sales growth in 2025 and a break-even point in 2026. Moderna is also working on nine late-stage pharmaceutical programs with planned milestones in 2024 and 2025.
